$elv 2020 Q4 10-K

Concept	2020 Q4	2020	2019 Q4
Revenue	$31.82B	$121.9B	$27.41B
YoY Change	16.12%	16.94%	17.26%
Cost Of Revenue		$8.953B
YoY Change		349.45%
Gross Profit		$112.9B
YoY Change		10.46%
Gross Profit Margin		92.65%
Selling, General & Admin	$4.272B	$17.45B	$3.502B
YoY Change	21.99%	30.57%	-3.21%
% of Gross Profit		15.45%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$290.0M	$176.0M	$246.0M
YoY Change	17.89%	19.73%	-14.58%
% of Gross Profit		0.16%
Operating Expenses	$30.97B	$17.45B	$26.12B
YoY Change	18.6%	30.57%	15.32%
Operating Profit		$6.360B
YoY Change		6.02%
Interest Expense	-$191.0M	$784.0M	-$190.0M
YoY Change	0.53%	5.09%	0.53%
% of Operating Profit		12.33%
Other Income/Expense, Net
YoY Change
Pretax Income	$611.0M	$6.238B	$1.098B
YoY Change	-44.35%	4.23%	102.58%
Income Tax	$60.00M	$1.666B	$164.0M
% Of Pretax Income	9.82%	26.71%	14.94%
Net Earnings	$551.0M	$4.572B	$934.0M
YoY Change	-41.01%	-4.89%	120.28%
Net Earnings / Revenue	1.73%	3.75%	3.41%
Basic Earnings Per Share	$2.23	$18.23	$3.69
Diluted Earnings Per Share	$2.19	$17.98	$3.62
COMMON SHARES
Basic Shares Outstanding	248.7M shares	250.8M shares	253.6M shares
Diluted Shares Outstanding		254.3M shares

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.17B		$24.61B
YoY Change	18.53%		19.33%
Cash & Equivalents	$5.741B	$5.741B	$4.937B
Short-Term Investments	$23.43B		$19.68B
Other Short-Term Assets	$4.060B		$3.020B
YoY Change	34.44%		43.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$45.75B		$39.03B
YoY Change	17.21%		13.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.483B	$4.129B	$3.133B
YoY Change	11.17%	11.35%	14.55%
Goodwill	$21.69B		$20.50B
YoY Change	5.81%		-0.02%
Intangibles	$9.405B		$8.674B
YoY Change	8.43%		-3.7%
Long-Term Investments	$29.84B	$29.84B	$25.46B
YoY Change	17.19%	17.19%	13.4%
Other Assets	$1.438B		$1.350B
YoY Change	6.52%		78.1%
Total Long-Term Assets	$40.86B		$38.42B
YoY Change	6.36%		3.14%
TOTAL ASSETS
Total Short-Term Assets	$45.75B		$39.03B
Total Long-Term Assets	$40.86B		$38.42B
Total Assets	$86.62B	$86.62B	$77.45B
YoY Change	11.83%	11.83%	8.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.493B	$5.493B	$4.198B
YoY Change	30.85%	30.85%	-15.35%
Accrued Expenses	$957.0M	$957.0M	$640.0M
YoY Change	49.53%	49.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$700.0M
YoY Change	-100.0%	-100.0%	-38.86%
Long-Term Debt Due	$700.0M	$700.0M	$1.598B
YoY Change	-56.2%	-56.2%	88.22%
Total Short-Term Liabilities	$29.45B	$7.150B	$23.53B
YoY Change	25.16%	-5.56%	7.13%
LONG-TERM LIABILITIES
Long-Term Debt	$19.34B	$19.34B	$17.79B
YoY Change	8.7%	8.7%	3.31%
Other Long-Term Liabilities	$1.815B	$6.910B	$1.420B
YoY Change	27.82%	54.52%	20.14%
Total Long-Term Liabilities	$21.15B	$26.25B	$19.21B
YoY Change	10.12%	17.91%	4.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.45B	$7.150B	$23.53B
Total Long-Term Liabilities	$21.15B	$26.25B	$19.21B
Total Liabilities	$53.42B	$53.42B	$45.73B
YoY Change	16.82%	16.82%	6.26%
SHAREHOLDERS EQUITY
Retained Earnings	$23.80B		$22.57B
YoY Change	5.44%		12.93%
Common Stock	$3.000M		$3.000M
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$33.20B	$33.20B	$31.73B
YoY Change
Total Liabilities & Shareholders Equity	$86.62B	$86.62B	$77.45B
YoY Change	11.83%	11.83%	8.22%

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	$551.0M	$4.572B	$934.0M
YoY Change	-41.01%	-4.89%	120.28%
Depreciation, Depletion And Amortization	$290.0M	$176.0M	$246.0M
YoY Change	17.89%	19.73%	-14.58%
Cash From Operating Activities	$3.813B	$10.69B	$1.327B
YoY Change	187.34%	76.34%	186.61%
INVESTING ACTIVITIES
Capital Expenditures	-$278.0M	$1.021B	-$351.0M
YoY Change	-20.8%	-5.2%	9.69%
Acquisitions		$1.976B
YoY Change
Other Investing Activities	$583.0M	$45.00M	$1.074B
YoY Change	-45.72%	-10.0%	-1.74%
Cash From Investing Activities	$305.0M	-$7.324B	$723.0M
YoY Change	-57.81%	162.32%	-6.47%
FINANCING ACTIVITIES
Cash Dividend Paid	$234.0M	$954.0M	$202.0M
YoY Change	15.84%	16.63%	4.66%
Common Stock Issuance & Retirement, Net		$2.700B
YoY Change		58.73%
Debt Paid & Issued, Net		$1.932B
YoY Change		72.04%
Cash From Financing Activities	-2.367B	-$2.567B	-1.304B
YoY Change	81.52%	13.28%	-16.46%
NET CHANGE
Cash From Operating Activities	3.813B	$10.69B	1.327B
Cash From Investing Activities	305.0M	-$7.324B	723.0M
Cash From Financing Activities	-2.367B	-$2.567B	-1.304B
Net Change In Cash	1.751B	$804.0M	746.0M
YoY Change	134.72%	-19.84%	-329.54%
FREE CASH FLOW
Cash From Operating Activities	$3.813B	$10.69B	$1.327B
Capital Expenditures	-$278.0M	$1.021B	-$351.0M
Free Cash Flow	$4.091B	$9.667B	$1.678B
YoY Change	143.8%	93.96%	114.3%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001156039
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q2	dei	Entity Public Float EntityPublicFloat	66230779383	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	244905689	shares
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22222000000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19021000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	7000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	532000000	USD
CY2019Q4	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	487000000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	245401430	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	252922161	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	245401430	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	252922161	shares
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	160000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	198000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-133000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-13000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-4000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	13000000	USD
CY2020	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities	0	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities	1000000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	3000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-4000000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	10000000	USD
CY2020	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	2000000	USD
CY2019	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	9000000	USD
CY2018	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-29000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-2000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	154000000	USD
CY2020	dei	City Area Code CityAreaCode	(800)
CY2020	dei	Local Phone Number LocalPhoneNumber	331-1476
CY2019	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	199000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-140000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilities
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-16751
CY2020	dei	Entity Registrant Name EntityRegistrantName	ANTHEM, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IN
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2145715
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	220 Virginia Avenue
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Indianapolis
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46204
CY2020	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01
CY2020	dei	Trading Symbol TradingSymbol	ANTM
CY2020	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	66230779383	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	244905689	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5741000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	23433000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	19676000000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	39033000000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	562000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	505000000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1559000000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1009000000	USD
CY2020Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5279000000	USD
CY2019Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5014000000	USD
CY2020Q4	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2849000000	USD
CY2019Q4	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2570000000	USD
CY2020Q4	us-gaap	Other Receivables OtherReceivables	2830000000	USD
CY2019Q4	us-gaap	Other Receivables OtherReceivables	2807000000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4060000000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3020000000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	45751000000	USD
CY2020Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	4285000000	USD
CY2019Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	4258000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3483000000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3133000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21691000000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	20500000000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9405000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8674000000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1438000000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1350000000	USD
CY2020Q4	us-gaap	Assets Assets	86615000000	USD
CY2019Q4	us-gaap	Assets Assets	77453000000	USD
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	11359000000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	8842000000	USD
CY2020Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4590000000	USD
CY2019Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	3050000000	USD
CY2020Q4	us-gaap	Unearned Premiums UnearnedPremiums	1259000000	USD
CY2019Q4	us-gaap	Unearned Premiums UnearnedPremiums	1017000000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5493000000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4198000000	USD
CY2020Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2019Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	700000000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	700000000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1598000000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6052000000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4127000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29453000000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23532000000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19335000000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17787000000	USD
CY2020Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	794000000	USD
CY2019Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	759000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2019000000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2227000000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	150000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1815000000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1420000000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	53416000000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	45725000000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9244000000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9448000000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	23802000000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	22573000000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-296000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	33199000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	31728000000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86615000000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77453000000	USD
CY2020	us-gaap	Premiums Earned Net PremiumsEarnedNet	104109000000	USD
CY2019	us-gaap	Premiums Earned Net PremiumsEarnedNet	94173000000	USD
CY2018	us-gaap	Premiums Earned Net PremiumsEarnedNet	85421000000	USD
CY2020	antm	Product Revenue ProductRevenue	10384000000	USD
CY2019	antm	Product Revenue ProductRevenue	2760000000	USD
CY2018	antm	Product Revenue ProductRevenue	0	USD
CY2020	us-gaap	Other Income OtherIncome	6315000000	USD
CY2019	us-gaap	Other Income OtherIncome	6208000000	USD
CY2018	us-gaap	Other Income OtherIncome	5920000000	USD
CY2020	antm	Operating Revenue OperatingRevenue	120808000000	USD
CY2019	antm	Operating Revenue OperatingRevenue	103141000000	USD
CY2018	antm	Operating Revenue OperatingRevenue	91341000000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	877000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1005000000	USD
CY2018	us-gaap	Net Investment Income NetInvestmentIncome	970000000	USD
CY2020	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	182000000	USD
CY2019	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	67000000	USD
CY2018	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	-206000000	USD
CY2020	us-gaap	Revenues Revenues	121867000000	USD
CY2019	us-gaap	Revenues Revenues	104213000000	USD
CY2018	us-gaap	Revenues Revenues	92105000000	USD
CY2020	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	88045000000	USD
CY2019	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	81786000000	USD
CY2018	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	71895000000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8953000000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1992000000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17450000000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13364000000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14020000000	USD
CY2020	us-gaap	Interest Expense InterestExpense	784000000	USD
CY2019	us-gaap	Interest Expense InterestExpense	746000000	USD
CY2018	us-gaap	Interest Expense InterestExpense	753000000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	361000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	338000000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	358000000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36000000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2000000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-11000000	USD
CY2020	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	115629000000	USD
CY2019	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	98228000000	USD
CY2018	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	87037000000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6238000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5985000000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5068000000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1666000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1178000000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1318000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	4572000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3750000000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	18.23
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	18.81
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.53
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	17.98
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	18.47
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	14.19
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.80
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.20
CY2018	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.00
CY2020	us-gaap	Net Income Loss NetIncomeLoss	4572000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3750000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	428000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	680000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-418000000	USD
CY2020	antm	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	0	USD
CY2019	antm	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	0	USD
CY2018	antm	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-2000000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	12000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-16000000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	37000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	1000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-26000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	90000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2019	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1133000000	USD
CY2018	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1132000000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-540000000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	81000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	446000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	690000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-474000000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5018000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5497000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3276000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	4572000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3750000000	USD
CY2020	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	182000000	USD
CY2019	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	67000000	USD
CY2018	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	-206000000	USD
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1154000000	USD
CY2020	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	3528000000	USD
CY2019	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1826000000	USD
CY2018	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-1059000000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	202000000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	115000000	USD
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-36000000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	1978000000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-445000000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	97000000	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	72000000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-325000000	USD
CY2018	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	323000000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	6000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	87000000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	91000000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	198000000	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	283000000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	294000000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	226000000	USD
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	256000000	USD
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1053000000	USD
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	695000000	USD
CY2020	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	32000000	USD
CY2019	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	48000000	USD
CY2018	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	1000000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	283000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	170000000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	26000000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1077000000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1208000000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	181000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10688000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6061000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3827000000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	19492000000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	22954000000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9671000000	USD
CY2020	antm	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	11318000000	USD
CY2019	antm	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	18598000000	USD
CY2018	antm	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	9662000000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4741000000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2437000000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1938000000	USD
CY2020	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	849000000	USD
CY2019	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	-254000000	USD
CY2018	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	149000000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1976000000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1760000000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1021000000	USD
CY2019	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	7590000000	USD
CY2018	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	9120000000	USD
CY2020	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1670000000	USD
CY2019	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	8035000000	USD
CY2018	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	9250000000	USD
CY2020	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	849000000	USD
CY2019	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	-254000000	USD
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	45000000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	50000000	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	71000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7324000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2792000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1259000000	USD
CY2020	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-150000000	USD
CY2019	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-297000000	USD
CY2018	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-107000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2484000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2473000000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	835000000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1932000000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1123000000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1684000000	USD
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	970000000	USD
CY2018	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	150000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1250000000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2700000000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1701000000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1685000000	USD
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends	954000000	USD
CY2019	us-gaap	Payments Of Dividends PaymentsOfDividends	818000000	USD
CY2018	us-gaap	Payments Of Dividends PaymentsOfDividends	776000000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	176000000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	187000000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	173000000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	128000000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	84000000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	81000000	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	488000000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-204000000	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-186000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2567000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2266000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2241000000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	7000000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2000000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	804000000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1003000000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	325000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3934000000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3609000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5741000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3934000000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	26503000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3750000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-474000000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1250000000	USD
CY2018	antm	Net Adjustment To Additional Paid In Capital For Equity Hedge NetAdjustmentToAdditionalPaidInCapitalForEquityHedge	1000000	USD
CY2018	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1685000000	USD
CY2018	us-gaap	Dividends Common Stock DividendsCommonStock	785000000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	318000000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-337000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	28541000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	690000000	USD
CY2019	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1701000000	USD
CY2019	us-gaap	Dividends Common Stock DividendsCommonStock	822000000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	396000000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-209000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	31728000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	4572000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	4572000000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	242000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	446000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	446000000	USD
CY2020	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	2700000000	USD
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	961000000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	330000000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-181000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	33199000000	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Organization <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 43 medical members through our affiliated health plans as of December 31, 2020. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations (“PPOs”); Health Maintenance Organizations (“HMOs”); Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as pharmacy benefits management (“PBM”), dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states across the country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or UniCare. Also, in the second quarter of 2019, we began providing PBM services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all 50 states and the District of Columbia through our subsidiaries.</span></div>
CY2020Q4	antm	Number Of Medical Members Served NumberOfMedicalMembersServed	43000000	medical_member
CY2020Q4	antm	Number Of Counties In Geographical Region Not Served NumberOfCountiesInGeographicalRegionNotServed	30	counties
CY2020Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	50	states
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior year amounts have been reclassified to conform to the current year presentation.</span>
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span>
CY2020Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	170000000	USD
CY2019Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	215000000	USD
CY2020	antm	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.02
CY2020Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	146000000	USD
CY2019Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	237000000	USD
CY2020Q4	antm	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	54000000	USD
CY2019Q4	antm	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	46000000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	374000000	USD
CY2020	us-gaap	Defined Benefit Plan Alternative Method Used To Amortize Net Gains And Losses DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses	We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.
CY2020	antm	Reserves For Future Policy Benefits Maximum Payable Period ReservesForFuturePolicyBenefitsMaximumPayablePeriod	P1Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.90
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	558000000	USD
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	467000000	USD
CY2018	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	385000000	USD
CY2018Q4	antm	Patient Protection Affordable Care Act Health Insurance Provider Fee PatientProtectionAffordableCareActHealthInsuranceProviderFee	14300000000	USD
CY2020Q4	antm	Patient Protection Affordable Care Act Health Insurance Provider Fee PatientProtectionAffordableCareActHealthInsuranceProviderFee	15523000000	USD
CY2020	antm	Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid	1570000000	USD
CY2018	antm	Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid	1544000000	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	258000000	USD
CY2020	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	653000000	USD
CY2020Q4	antm	Equity Securities EquitySecurities	1559000000	USD
CY2019Q4	antm	Equity Securities EquitySecurities	1009000000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	915000000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	1034000000	USD
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	1011000000	USD
CY2020	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	38000000	USD
CY2019	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	29000000	USD
CY2018	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	41000000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	877000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1005000000	USD
CY2018	us-gaap	Net Investment Income NetInvestmentIncome	970000000	USD
CY2020	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	184000000	USD
CY2019	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	84000000	USD
CY2018	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-229000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	570000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	874000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-524000000	USD
CY2020	antm	Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments	142000000	USD
CY2019	antm	Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments	194000000	USD
CY2018	antm	Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments	-106000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	428000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	680000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-418000000	USD
CY2020	antm	Net Realized Gains Losses On Investments And Net Change In Net Unrealized Gains Losses On Investments NetRealizedGainsLossesOnInvestmentsAndNetChangeInNetUnrealizedGainsLossesOnInvestments	612000000	USD
CY2019	antm	Net Realized Gains Losses On Investments And Net Change In Net Unrealized Gains Losses On Investments NetRealizedGainsLossesOnInvestmentsAndNetChangeInNetUnrealizedGainsLossesOnInvestments	764000000	USD
CY2018	antm	Net Realized Gains Losses On Investments And Net Change In Net Unrealized Gains Losses On Investments NetRealizedGainsLossesOnInvestmentsAndNetChangeInNetUnrealizedGainsLossesOnInvestments	-647000000	USD
CY2020Q4	antm	Number Of Fixed Maturity Investments That Did Not Produce Income NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome	3
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	1320000000	USD
CY2019Q4	us-gaap	Contractual Obligation ContractualObligation	999000000	USD
CY2019	antm	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.03
CY2020Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	562000000	USD
CY2019Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	505000000	USD
CY2020Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	1199000000	USD
CY2019Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	351000000	USD
CY2020	antm	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.02
CY2020Q4	us-gaap	Derivative Asset Collateral Obligation To Return Cash Offset DerivativeAssetCollateralObligationToReturnCashOffset	37000000	USD
CY2019Q4	us-gaap	Derivative Asset Collateral Obligation To Return Cash Offset DerivativeAssetCollateralObligationToReturnCashOffset	22000000	USD
CY2020Q4	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	785000000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	43000000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	5000000	USD
CY2020Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	0	USD
CY2020Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	0	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	43000000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	5000000	USD
CY2019Q4	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	1335000000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	23000000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1000000	USD
CY2019Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	1000000	USD
CY2019Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	1000000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	22000000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	0	USD
CY2020	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	182000000	USD
CY2019	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	67000000	USD
CY2018	antm	Net Realized Gains Losses On Financial Instruments NetRealizedGainsLossesOnFinancialInstruments	-206000000	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2000000	USD
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-17000000	USD
CY2018	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	23000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3163000000	USD
CY2020Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	1199000000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	29959000000	USD
CY2020Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	5000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2015000000	USD
CY2019Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	353000000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	23581000000	USD
CY2019Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1000000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	397000000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-22000000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	-5000000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	101000000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	41000000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	46000000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	10000000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	2000000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	392000000	USD
CY2020	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-19000000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	623000000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-13000000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	3000000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	189000000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	101000000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	79000000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	5000000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	230000000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	397000000	USD
CY2019	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	6000000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	537000000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-228000000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	-5000000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	430000000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	69000000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	99000000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	74000000	USD

CY2020

dei

Amendment Flag

AmendmentFlag

false

CY2020

dei

Document Period End Date

DocumentPeriodEndDate

2020-12-31

CY2020

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2020

CY2020

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

FY

CY2020

dei

Entity Central Index Key

EntityCentralIndexKey

0001156039

CY2020

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2020Q2

dei

Entity Public Float

EntityPublicFloat

66230779383

USD

CY2021Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

244905689

shares

CY2020Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

22222000000

USD

CY2019Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

19021000000

USD

CY2020Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

7000000

USD

CY2019Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

0

USD

CY2020Q4

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

532000000

USD

CY2019Q4

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

487000000

USD

CY2020Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2019Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2020Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2019Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2020Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2019Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2020Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2019Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2020Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2019Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2020Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2019Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2020Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

245401430

shares

CY2019Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

252922161

shares

CY2020Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

245401430

shares

CY2019Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

252922161

shares

CY2020

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

160000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

198000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

-133000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

-13000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

-4000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

13000000

USD

CY2020

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities

0

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities

0

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities

1000000

USD

CY2020

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

3000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

-4000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

10000000

USD

CY2020

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

2000000

USD

CY2019

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

9000000

USD

CY2018

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-29000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

-2000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

CY2018

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

CY2020

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

154000000

USD

CY2020

dei

City Area Code

CityAreaCode

(800)

CY2020

dei

Local Phone Number

LocalPhoneNumber

331-1476

CY2019

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

199000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-140000000

USD

CY2020Q4

us-gaap

Operating Lease Liability Statement Of Financial Position Extensible List

OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList

us-gaap:OtherLiabilities

CY2020

dei

Document Type

DocumentType

10-K

CY2020

dei

Document Annual Report

DocumentAnnualReport

true

CY2020

dei

Document Transition Report

DocumentTransitionReport

false

CY2020

dei

Entity File Number

EntityFileNumber

001-16751

CY2020

dei

Entity Registrant Name

EntityRegistrantName

ANTHEM, INC.

CY2020

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

IN

CY2020

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

35-2145715

CY2020

dei

Entity Address Address Line1

EntityAddressAddressLine1

220 Virginia Avenue

CY2020

dei

Entity Address City Or Town

EntityAddressCityOrTown

Indianapolis

CY2020

dei

Entity Address State Or Province

EntityAddressStateOrProvince

IN

CY2020

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

46204

CY2020

dei

Security12b Title

Security12bTitle

Common Stock, Par Value $0.01

CY2020

dei

Trading Symbol

TradingSymbol

ANTM

CY2020

dei

Security Exchange Name

SecurityExchangeName

NYSE

CY2020

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2020

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2020

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2020

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2020

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2020

dei

Entity Small Business

EntitySmallBusiness

false

CY2020

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2020

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

true

CY2020

dei

Entity Shell Company

EntityShellCompany

false

CY2020Q2

dei

Entity Public Float

EntityPublicFloat

66230779383

USD

CY2021Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

244905689

shares

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

5741000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2020Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

23433000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

19676000000

USD

CY2019Q4

us-gaap

Assets Current

AssetsCurrent

39033000000

USD

CY2020Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

562000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

505000000

USD

CY2020Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

1559000000

USD

CY2019Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

1009000000

USD

CY2020Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5279000000

USD

CY2019Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5014000000

USD

CY2020Q4

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2849000000

USD

CY2019Q4

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2570000000

USD

CY2020Q4

us-gaap

Other Receivables

OtherReceivables

2830000000

USD

CY2019Q4

us-gaap

Other Receivables

OtherReceivables

2807000000

USD

CY2020Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

4060000000

USD

CY2019Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

3020000000

USD

CY2020Q4

us-gaap

Assets Current

AssetsCurrent

45751000000

USD

CY2020Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

4285000000

USD

CY2019Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

4258000000

USD

CY2020Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3483000000

USD

CY2019Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3133000000

USD

CY2020Q4

us-gaap

Goodwill

21691000000

USD

CY2019Q4

us-gaap

Goodwill

20500000000

USD

CY2020Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9405000000

USD

CY2019Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

8674000000

USD

CY2020Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1438000000

USD

CY2019Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1350000000

USD

CY2020Q4

us-gaap

Assets

86615000000

USD

CY2019Q4

us-gaap

Assets

77453000000

USD

CY2020Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

11359000000

USD

CY2019Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

8842000000

USD

CY2020Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

4590000000

USD

CY2019Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

3050000000

USD

CY2020Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1259000000

USD

CY2019Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1017000000

USD

CY2020Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

5493000000

USD

CY2019Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

4198000000

USD

CY2020Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

0

USD

CY2019Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

700000000

USD

CY2020Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

700000000

USD

CY2019Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1598000000

USD

CY2020Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

6052000000

USD

CY2019Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

4127000000

USD

CY2020Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

29453000000

USD

CY2019Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

23532000000

USD

CY2020Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

19335000000

USD

CY2019Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17787000000

USD

CY2020Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

794000000

USD

CY2019Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

759000000

USD

CY2020Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2019000000

USD

CY2019Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2227000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

150000000

USD

CY2020Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1815000000

USD

CY2019Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1420000000

USD

CY2020Q4

us-gaap

Liabilities

53416000000

USD

CY2019Q4

us-gaap

Liabilities

45725000000

USD

CY2020Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2019Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2020Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2019Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2020Q4

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2019Q4

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2020Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9244000000

USD

CY2019Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9448000000

USD

CY2020Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

23802000000

USD

CY2019Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

22573000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-296000000

USD

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

33199000000

USD

CY2019Q4

us-gaap

Stockholders Equity

StockholdersEquity

31728000000

USD

CY2020Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

86615000000

USD

CY2019Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

77453000000

USD

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2018

us-gaap

Premiums Earned Net

PremiumsEarnedNet

85421000000

USD

CY2020

antm

Product Revenue

ProductRevenue

10384000000

USD

CY2019

antm

Product Revenue

ProductRevenue

2760000000

USD

CY2018

antm

Product Revenue

ProductRevenue

0

USD

CY2020

us-gaap

Other Income

OtherIncome

6315000000

USD

CY2019

us-gaap

Other Income

OtherIncome

6208000000

USD

CY2018

us-gaap

Other Income

OtherIncome

5920000000

USD

CY2020

antm

Operating Revenue

OperatingRevenue

120808000000

USD

CY2019

antm

Operating Revenue

OperatingRevenue

103141000000

USD

CY2018

antm

Operating Revenue

OperatingRevenue

91341000000

USD

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2018

us-gaap

Net Investment Income

NetInvestmentIncome

970000000

USD

CY2020

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

182000000

USD

CY2019

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

67000000

USD

CY2018

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

-206000000

USD

CY2020

us-gaap

Revenues

121867000000

USD

CY2019

us-gaap

Revenues

104213000000

USD

CY2018

us-gaap

Revenues

92105000000

USD

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2018

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

71895000000

USD

CY2020

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

8953000000

USD

CY2019

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

1992000000

USD

CY2018

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

0

USD

CY2020

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

17450000000

USD

CY2019

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

13364000000

USD

CY2018

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

14020000000

USD

CY2020

us-gaap

Interest Expense

InterestExpense

784000000

USD

CY2019

us-gaap

Interest Expense

InterestExpense

746000000

USD

CY2018

us-gaap

Interest Expense

InterestExpense

753000000

USD

CY2020

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

361000000

USD

CY2019

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

338000000

USD

CY2018

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

358000000

USD

CY2020

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-36000000

USD

CY2019

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-2000000

USD

CY2018

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-11000000

USD

CY2020

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

115629000000

USD

CY2019

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

98228000000

USD

CY2018

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

87037000000

USD

CY2020

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

6238000000

USD

CY2019

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5985000000

USD

CY2018

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5068000000

USD

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

USD

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2018

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1318000000

USD

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

4572000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2018

us-gaap

Net Income Loss

NetIncomeLoss

3750000000

USD

CY2020

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

18.23

CY2019

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

18.81

CY2018

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

14.53

CY2020

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

17.98

CY2019

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

18.47

CY2018

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

14.19

CY2020

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.80

CY2019

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.20

CY2018

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.00

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

4572000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2018

us-gaap

Net Income Loss

NetIncomeLoss

3750000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

428000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

680000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-418000000

USD

CY2020

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

0

USD

CY2019

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

0

USD

CY2018

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-2000000

USD

CY2020

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

12000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

-16000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

37000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

1000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-26000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

90000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

7000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

CY2019

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1133000000

USD

CY2018

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1132000000

USD

CY2020

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-540000000

USD

CY2019

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

81000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-1000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

446000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

690000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-474000000

USD

CY2020

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

5018000000

USD

CY2019

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

5497000000

USD

CY2018

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

3276000000

USD

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

4572000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2018

us-gaap

Net Income Loss

NetIncomeLoss

3750000000

USD

CY2020

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

182000000

USD

CY2019

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

67000000

USD

CY2018

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

-206000000

USD

CY2020

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1154000000

USD

CY2020

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

3528000000

USD

CY2019

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

1826000000

USD

CY2018

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

-1059000000

USD

CY2020

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

202000000

USD

CY2019

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

115000000

USD

CY2018

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

-36000000

USD

CY2020

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

1978000000

USD

CY2019

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

-445000000

USD

CY2018

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

97000000

USD

CY2020

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

72000000

USD

CY2019

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

-325000000

USD

CY2018

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

323000000

USD

CY2020

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

6000000

USD

CY2019

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

87000000

USD

CY2018

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

91000000

USD

CY2020

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

198000000

USD

CY2019

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

USD

CY2018

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

USD

CY2020

us-gaap

Share Based Compensation

ShareBasedCompensation

283000000

USD

CY2019

us-gaap

Share Based Compensation

ShareBasedCompensation

294000000

USD

CY2018

us-gaap

Share Based Compensation

ShareBasedCompensation

226000000

USD

CY2020

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

256000000

USD

CY2019

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

1053000000

USD

CY2018

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

695000000

USD

CY2020

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

32000000

USD

CY2019

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

48000000

USD

CY2018

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

1000000

USD

CY2020

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

283000000

USD

CY2019

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

170000000

USD

CY2018

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

26000000

USD

CY2019

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1077000000

USD

CY2018

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1208000000

USD

CY2018

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

181000000

USD

CY2020

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

10688000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

6061000000

USD

CY2018

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

3827000000

USD

CY2020

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

19492000000

USD

CY2019

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

22954000000

USD

CY2018

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

9671000000

USD

CY2020

antm

Proceedsfromsaleofequityandfixedmaturitysecurities

11318000000

USD

CY2019

antm

Proceedsfromsaleofequityandfixedmaturitysecurities

18598000000

USD

CY2018

antm

Proceedsfromsaleofequityandfixedmaturitysecurities

9662000000

USD

CY2020

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

4741000000

USD

CY2019

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

2437000000

USD

CY2018

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

1938000000

USD

CY2020

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

849000000

USD

CY2019

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

-254000000

USD

CY2018

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

149000000

USD

CY2020

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1976000000

USD

CY2019

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

USD

CY2018

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1760000000

USD

CY2020

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1021000000

USD

CY2019

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

7590000000

USD

CY2018

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

9120000000

USD

CY2020

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1670000000

USD

CY2019

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

8035000000

USD

CY2018

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

9250000000

USD

CY2020

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

849000000

USD

CY2019

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-254000000

USD

CY2020

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

45000000

USD

CY2019

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

50000000

USD

CY2018

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

71000000

USD

CY2020

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-7324000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-2792000000

USD

CY2018

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-1259000000

USD

CY2020

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-150000000

USD

CY2019

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-297000000

USD

CY2018

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-107000000

USD

CY2020

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2484000000

USD

CY2019

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2473000000

USD

CY2018

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

835000000

USD

CY2020

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1932000000

USD

CY2019

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1123000000

USD

CY2018

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1684000000

USD

CY2020

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

970000000

USD

CY2018

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

150000000

USD

CY2020

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

0

USD

CY2019

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

0

USD

CY2018

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

1250000000

USD

CY2020

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

2700000000

USD

CY2019

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1701000000

USD

CY2018

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1685000000

USD

CY2020

us-gaap

Payments Of Dividends

PaymentsOfDividends

954000000

USD

CY2019

us-gaap

Payments Of Dividends

PaymentsOfDividends

818000000

USD

CY2018

us-gaap

Payments Of Dividends

PaymentsOfDividends

776000000

USD

CY2020

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

176000000

USD

CY2019

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

187000000

USD

CY2018

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

173000000

USD

CY2020

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

128000000

USD

CY2019

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

84000000

USD

CY2018

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

81000000

USD

CY2020

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

488000000

USD

CY2019

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-204000000

USD

CY2018

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-186000000

USD

CY2020

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-2567000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-2266000000

USD

CY2018

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-2241000000

USD

CY2020

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

7000000

USD

CY2019

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

0

USD

CY2018

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

-2000000

USD

CY2020

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

804000000

USD

CY2019

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

1003000000

USD

CY2018

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

325000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3934000000

USD

CY2017Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3609000000

USD

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

5741000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3934000000

USD

CY2017Q4

us-gaap

Stockholders Equity

StockholdersEquity

26503000000

USD

CY2018

us-gaap

Net Income Loss

NetIncomeLoss

3750000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-474000000

USD

CY2018

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

1250000000

USD

CY2018

antm

Net Adjustment To Additional Paid In Capital For Equity Hedge

NetAdjustmentToAdditionalPaidInCapitalForEquityHedge

1000000

USD

CY2018

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1685000000

USD

CY2018

us-gaap

Dividends Common Stock

DividendsCommonStock

785000000

USD

CY2018

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

318000000

USD

CY2018

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-337000000

USD

CY2018Q4

us-gaap

Stockholders Equity

StockholdersEquity

28541000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

690000000

USD

CY2019

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1701000000

USD

CY2019

us-gaap

Dividends Common Stock

DividendsCommonStock

822000000

USD

CY2019

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

396000000

USD

CY2019

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-209000000

USD

CY2019Q4

us-gaap

Stockholders Equity

StockholdersEquity

31728000000

USD

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

4572000000

USD

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

4572000000

USD

CY2019Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

242000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

446000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

446000000

USD

CY2020

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

2700000000

USD

CY2020

us-gaap

Dividends Common Stock

DividendsCommonStock

961000000

USD

CY2020

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

330000000

USD

CY2020

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-181000000

USD

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

33199000000

USD

CY2020

us-gaap

Nature Of Operations

NatureOfOperations

Organization <div style="margin-bottom:9pt;text-indent:18pt">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. </div><div style="margin-bottom:9pt;text-indent:18pt">We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 43 medical members through our affiliated health plans as of December 31, 2020. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations (“PPOs”); Health Maintenance Organizations (“HMOs”); Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as pharmacy benefits management (“PBM”), dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. </div><div style="margin-bottom:12pt;text-indent:18pt">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states across the country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or UniCare. Also, in the second quarter of 2019, we began providing PBM services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all 50 states and the District of Columbia through our subsidiaries.</div>

CY2020Q4

antm

Number Of Medical Members Served

NumberOfMedicalMembersServed

43000000

medical_member

CY2020Q4

antm

Number Of Counties In Geographical Region Not Served

NumberOfCountiesInGeographicalRegionNotServed

30

counties

CY2020Q4

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

states

CY2020

us-gaap

Prior Period Reclassification Adjustment Description

PriorPeriodReclassificationAdjustmentDescription

Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation.

CY2020

us-gaap

Use Of Estimates

UseOfEstimates

Use of Estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

CY2020Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

170000000

USD

CY2019Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

215000000

USD

CY2020

antm

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2020Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

146000000

USD

CY2019Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

237000000

USD

CY2020Q4

antm

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

54000000

USD

CY2019Q4

antm

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

46000000

USD

CY2020Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

374000000

USD

CY2020

us-gaap

Defined Benefit Plan Alternative Method Used To Amortize Net Gains And Losses

DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses

We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.

CY2020

antm

Reserves For Future Policy Benefits Maximum Payable Period

ReservesForFuturePolicyBenefitsMaximumPayablePeriod

P1Y

CY2020

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent

SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

0.90

CY2020

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

558000000

USD

CY2019

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

467000000

USD

CY2018

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

385000000

USD

CY2018Q4

antm

Patient Protection Affordable Care Act Health Insurance Provider Fee

PatientProtectionAffordableCareActHealthInsuranceProviderFee

14300000000

USD

CY2020Q4

antm

Patient Protection Affordable Care Act Health Insurance Provider Fee

PatientProtectionAffordableCareActHealthInsuranceProviderFee

15523000000

USD

CY2020

antm

Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid

PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid

1570000000

USD

CY2018

antm

Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid

PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid

1544000000

USD

CY2020

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

258000000

USD

CY2020

us-gaap

Restructuring And Related Cost Incurred Cost

RestructuringAndRelatedCostIncurredCost

653000000

USD

CY2020Q4

antm

Equity Securities

EquitySecurities

1559000000

USD

CY2019Q4

antm

Equity Securities

EquitySecurities

1009000000

USD

CY2020

us-gaap

Investment Income Net

InvestmentIncomeNet

915000000

USD

CY2019

us-gaap

Investment Income Net

InvestmentIncomeNet

1034000000

USD

CY2018

us-gaap

Investment Income Net

InvestmentIncomeNet

1011000000

USD

CY2020

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

38000000

USD

CY2019

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

29000000

USD

CY2018

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

41000000

USD

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2018

us-gaap

Net Investment Income

NetInvestmentIncome

970000000

USD

CY2020

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

184000000

USD

CY2019

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

84000000

USD

CY2018

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

-229000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

570000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

874000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

-524000000

USD

CY2020

antm

Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments

DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments

142000000

USD

CY2019

antm

Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments

DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments

194000000

USD

CY2018

antm

Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments

DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments

-106000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

428000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

680000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-418000000

USD

CY2020

antm

Net Realized Gains Losses On Investments And Net Change In Net Unrealized Gains Losses On Investments

NetRealizedGainsLossesOnInvestmentsAndNetChangeInNetUnrealizedGainsLossesOnInvestments

612000000

USD

CY2019

antm

Net Realized Gains Losses On Investments And Net Change In Net Unrealized Gains Losses On Investments

NetRealizedGainsLossesOnInvestmentsAndNetChangeInNetUnrealizedGainsLossesOnInvestments

764000000

USD

CY2018

antm

Net Realized Gains Losses On Investments And Net Change In Net Unrealized Gains Losses On Investments

NetRealizedGainsLossesOnInvestmentsAndNetChangeInNetUnrealizedGainsLossesOnInvestments

-647000000

USD

CY2020Q4

antm

Number Of Fixed Maturity Investments That Did Not Produce Income

NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome

3

CY2020Q4

us-gaap

Contractual Obligation

ContractualObligation

1320000000

USD

CY2019Q4

us-gaap

Contractual Obligation

ContractualObligation

999000000

USD

CY2019

antm

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.03

CY2020Q4

us-gaap

Assets Held By Insurance Regulators

AssetsHeldByInsuranceRegulators

562000000

USD

CY2019Q4

us-gaap

Assets Held By Insurance Regulators

AssetsHeldByInsuranceRegulators

505000000

USD

CY2020Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

1199000000

USD

CY2019Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

351000000

USD

CY2020

antm

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2020Q4

us-gaap

Derivative Asset Collateral Obligation To Return Cash Offset

DerivativeAssetCollateralObligationToReturnCashOffset

37000000

USD

CY2019Q4

us-gaap

Derivative Asset Collateral Obligation To Return Cash Offset

DerivativeAssetCollateralObligationToReturnCashOffset

22000000

USD

CY2020Q4

us-gaap

Derivative Notional Amount

DerivativeNotionalAmount

785000000

USD

CY2020Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

43000000

USD

CY2020Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

5000000

USD

CY2020Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

0

USD

CY2020Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

0

USD

CY2020Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

43000000

USD

CY2020Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

5000000

USD

CY2019Q4

us-gaap

Derivative Notional Amount

DerivativeNotionalAmount

1335000000

USD

CY2019Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

23000000

USD

CY2019Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

1000000

USD

CY2019Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

1000000

USD

CY2019Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

1000000

USD

CY2019Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

22000000

USD

CY2019Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

0

USD

CY2020

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

182000000

USD

CY2019

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

67000000

USD

CY2018

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

-206000000

USD

CY2020

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-2000000

USD

CY2019

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-17000000

USD

CY2018

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

23000000

USD

CY2020Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

3163000000

USD

CY2020Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

1199000000

USD

CY2020Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

29959000000

USD

CY2020Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

5000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2015000000

USD

CY2019Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

353000000

USD

CY2019Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

23581000000

USD

CY2019Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

1000000

USD

CY2019Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

397000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-22000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-5000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

101000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

41000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

46000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

10000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

2000000

USD

CY2020Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

392000000

USD

CY2020

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-19000000

USD

CY2018Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

623000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-13000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

3000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

189000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

101000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

79000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

5000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

230000000

USD

CY2019Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

397000000

USD

CY2019

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

6000000

USD

CY2017Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

537000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-228000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-5000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

430000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

69000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

99000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

74000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

17000000

USD

CY2018Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

623000000

USD

CY2018

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

30000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

588000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

331000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

143000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

89000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

187000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

139000000

USD

CY2020Q4

antm

Deferred Tax Assets Leasing Arrangements

DeferredTaxAssetsLeasingArrangements

204000000

USD

CY2019Q4

antm

Deferred Tax Assets Leasing Arrangements

DeferredTaxAssetsLeasingArrangements

180000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

205000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

216000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

31000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

28000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

274000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

124000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

113000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

71000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

1745000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

1178000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

84000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

45000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

1661000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

1133000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

2073000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

1999000000

USD

CY2020Q4

antm

Deferred Tax Liabilities Relating To Capitalized Software Other

DeferredTaxLiabilitiesRelatingToCapitalizedSoftwareOther

670000000

USD

CY2019Q4

antm

Deferred Tax Liabilities Relating To Capitalized Software Other

DeferredTaxLiabilitiesRelatingToCapitalizedSoftwareOther

554000000

USD

CY2019

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1019000000

USD

CY2018

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1064000000

USD

CY2020Q4

antm

Deferred Tax Assets Related To Depreciation And Amortization

DeferredTaxAssetsRelatedToDepreciationAndAmortization

37000000

USD

CY2019Q4

antm

Deferred Tax Assets Related To Depreciation And Amortization

DeferredTaxAssetsRelatedToDepreciationAndAmortization

62000000

USD

CY2020Q4

antm

Deferred Tax Liabilities Investment Basis

DeferredTaxLiabilitiesInvestmentBasis

407000000

USD

CY2019Q4

antm

Deferred Tax Liabilities Investment Basis

DeferredTaxLiabilitiesInvestmentBasis

230000000

USD

CY2020Q4

antm

Deferred Taxliabilities Deferred Expense Retirementbenefits

DeferredTaxliabilitiesDeferredExpenseRetirementbenefits

260000000

USD

CY2019Q4

antm

Deferred Taxliabilities Deferred Expense Retirementbenefits

DeferredTaxliabilitiesDeferredExpenseRetirementbenefits

249000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Leasing Arrangements

DeferredTaxLiabilitiesLeasingArrangements

131000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Leasing Arrangements

DeferredTaxLiabilitiesLeasingArrangements

164000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Prepaid Expenses

DeferredTaxLiabilitiesPrepaidExpenses

102000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Prepaid Expenses

DeferredTaxLiabilitiesPrepaidExpenses

102000000

USD

CY2020Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

3680000000

USD

CY2019Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

3360000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2019000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2227000000

USD

CY2020

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1731000000

USD

CY2020

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

79000000

USD

CY2019

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

84000000

USD

CY2018

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

78000000

USD

CY2020

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

461000000

USD

CY2020

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

2192000000

USD

CY2018

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1128000000

USD

CY2019

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1103000000

USD

CY2018

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1206000000

USD

CY2020

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

-526000000

USD

CY2019

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

75000000

USD

CY2018

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

112000000

USD

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

USD

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2018

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1318000000

USD

CY2020

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1310000000

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2019

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1257000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2018

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2020

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

235000000

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.038

CY2019

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

138000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.023

CY2018

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

63000000

USD

CY2018

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.012

CY2020

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

22000000

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.004

CY2019

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

24000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.004

CY2018

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

27000000

USD

CY2018

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.005

CY2020

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

330000000

USD

CY2020

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0.053

CY2019

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

0

USD

CY2019

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0

CY2018

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

324000000

USD

CY2018

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0.064

CY2020

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

-110000000

USD

CY2020

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

-0.018

CY2019

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

0

USD

CY2019

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

0

CY2018

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

-28000000

USD

CY2018

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

-0.006

CY2020

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

0

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate

EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate

0

CY2019

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

0

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate

EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate

0

CY2018

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

-28000000

USD

CY2018

us-gaap

Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate

EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate

-0.006

CY2020

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-77000000

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.012

CY2019

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-193000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.032

CY2018

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-50000000

USD

CY2018

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.009

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

USD

CY2020

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.267

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2019

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.197

CY2018

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1318000000

USD

CY2018

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.260

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

USD

CY2020

us-gaap

Unusual Or Infrequent Item Earnings Per Share Impact Net

UnusualOrInfrequentItemEarningsPerShareImpactNet

6.55

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2019

us-gaap

Unusual Or Infrequent Item Earnings Per Share Impact Net

UnusualOrInfrequentItemEarningsPerShareImpactNet

4.53

CY2019

antm

Reclassificationofstrandedtaxeffectsresultingfromthe Tax Cutsand Jobs Act

ReclassificationofstrandedtaxeffectsresultingfromtheTaxCutsandJobsAct

91000000

USD

CY2019Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

146000000

USD

CY2018Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

241000000

USD

CY2020

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

76000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

1000000

USD

CY2020

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

40000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

0

USD

CY2020

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

13000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

63000000

USD

CY2020

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities

UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

0

USD

CY2019

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities

UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

33000000

USD

CY2020Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

249000000

USD

CY2019Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

146000000

USD

CY2020Q4

us-gaap

Unrecognized Tax Benefits That Would Impact Effective Tax Rate

UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

227000000

USD

CY2019Q4

us-gaap

Unrecognized Tax Benefits That Would Impact Effective Tax Rate

UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

140000000

USD

CY2020Q4

antm

Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate In Future Periods If Recognized

UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized

2000000

USD

CY2017

antm

Income Tax Refund Claims Filed

IncomeTaxRefundClaimsFiled

310000000

USD

CY2020

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-7000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

11000000

USD

CY2018

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-15000000

USD

CY2020Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

33000000

USD

CY2019Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

26000000

USD

CY2020Q4

us-gaap

Decrease In Unrecognized Tax Benefits Is Reasonably Possible

DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

15000000

USD

CY2020Q4

us-gaap

Increase In Unrecognized Tax Benefits Is Reasonably Possible

IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

147000000

USD

CY2020

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1790000000

USD

CY2019

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1403000000

USD

CY2018

us-gaap

Income Taxes Paid

IncomeTaxesPaid

738000000

USD

CY2020Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

7327000000

USD

CY2019Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

6479000000

USD

CY2020Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

3844000000

USD

CY2019Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

3346000000

USD

CY2020Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3483000000

USD

CY2019Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3133000000

USD

CY2020

us-gaap

Depreciation

176000000

USD

CY2019

us-gaap

Depreciation

147000000

USD

CY2018

us-gaap

Depreciation

124000000

USD

CY2020

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

462000000

USD

CY2019

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

528000000

USD

CY2018

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

528000000

USD

CY2020

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

412000000

USD

CY2019

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

450000000

USD

CY2018

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

465000000

USD

CY2020Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

4783000000

USD

CY2019Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

3939000000

USD

CY2020

us-gaap

Impairment Of Long Lived Assets To Be Disposed Of

ImpairmentOfLongLivedAssetsToBeDisposedOf

198000000

USD

CY2018Q4

us-gaap

Goodwill

20504000000

USD

CY2019

us-gaap

Goodwill Period Increase Decrease

GoodwillPeriodIncreaseDecrease

-4000000

USD

CY2019Q4

us-gaap

Goodwill

20500000000

USD

CY2020

us-gaap

Goodwill Period Increase Decrease

GoodwillPeriodIncreaseDecrease

1191000000

USD

CY2020Q4

us-gaap

Goodwill

21691000000

USD

CY2020Q4

us-gaap

Goodwill Impaired Accumulated Impairment Loss

GoodwillImpairedAccumulatedImpairmentLoss

41000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Gross

FiniteLivedIntangibleAssetsGross

5947000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

4057000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

1890000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Gross

FiniteLivedIntangibleAssetsGross

5080000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

3696000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

1384000000

USD

CY2020Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7515000000

USD

CY2020Q4

antm

Intangible Assets Accumulated Amortization Excluding Goodwill

IntangibleAssetsAccumulatedAmortizationExcludingGoodwill

4057000000

USD

CY2020Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7515000000

USD

CY2019Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7290000000

USD

CY2019Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7290000000

USD

CY2020Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

13462000000

USD

CY2020Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9405000000

USD

CY2019Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

12370000000

USD

CY2019Q4

antm

Intangible Assets Accumulated Amortization Excluding Goodwill

IntangibleAssetsAccumulatedAmortizationExcludingGoodwill

3696000000

USD

CY2019Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

8674000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

324000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

271000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

233000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

196000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

159000000

USD

CY2020

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-29000000

USD

CY2019

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-9000000

USD

CY2018

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-5000000

USD

CY2020Q4

antm

Defined Benefit Fair Value Due From Brokers

DefinedBenefitFairValueDueFromBrokers

64000000

USD

CY2019Q4

antm

Defined Benefit Fair Value Due From Brokers

DefinedBenefitFairValueDueFromBrokers

64000000

USD

CY2020

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

221000000

USD

CY2019

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

201000000

USD

CY2018

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

211000000

USD

CY2018

us-gaap

Defined Contribution Plan Increase Decrease Cost

DefinedContributionPlanIncreaseDecreaseCost

58000000

USD

CY2020

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-bottom:9pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, “Segment Information”), for the year ended December 31, 2020 is as follows:</div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,039 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,608 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,647 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(33)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,025 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,589 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,614 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Business combinations and purchase adjustments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">339 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,894 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,912 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,094 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(375)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(262)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(637)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,519 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,650 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,288 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,457 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,736 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51,602 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,291 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,629 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,527 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,165 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,692 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,263 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,767 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,291 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,321 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,281 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,613 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,089 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,294 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,646 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,135 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt">Activity in our Other segment resulted from our acquisition of Beacon.</div><div style="margin-bottom:3pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2019 is as follows:</div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,586 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,680 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,266 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,576 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,656 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,232 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,942 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52,753 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78,695 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(190)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(310)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(500)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,752 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52,443 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78,195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,026 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,268 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,294 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,277 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,242 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,519 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,303 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51,510 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76,813 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,025 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,589 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,614 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,039 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,608 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,647 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2018 is as follows:</div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,383 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,431 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,814 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(78)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(105)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,305 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,404 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,709 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Business combinations and purchase adjustments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">199 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">199 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,094 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,487 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,581 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(456)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(474)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(930)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,638 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,013 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,651 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,633 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,115 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,748 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,734 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,845 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,579 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,367 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44,960 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,327 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,576 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,656 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,232 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,586 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,680 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,266 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

CY2019Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8647000000

USD

CY2019Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

33000000

USD

CY2019Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

8614000000

USD

CY2020Q4

antm

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

339000000

USD

CY2020

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

85094000000

USD

CY2020

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

637000000

USD

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

84457000000

USD

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

74629000000

USD

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

7692000000

USD

CY2020

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

82321000000

USD

CY2020Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

11089000000

USD

CY2020Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

46000000

USD

CY2020Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

11135000000

USD

CY2018Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7266000000

USD

CY2018Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2018Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7232000000

USD

CY2019

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

78695000000

USD

CY2019

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

500000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

78195000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

70294000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

6519000000

USD

CY2019

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

76813000000

USD

CY2019Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

8614000000

USD

CY2019Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

33000000

USD

CY2019Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8647000000

USD

CY2017Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7814000000

USD

CY2017Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

105000000

USD

CY2017Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7709000000

USD

CY2018Q4

antm

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

199000000

USD

CY2018

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

69581000000

USD

CY2018

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

930000000

USD

CY2018

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

68651000000

USD

CY2018

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

62748000000

USD

CY2018

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

6579000000

USD

CY2018

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

69327000000

USD

CY2018Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7232000000

USD

CY2018Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2018Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7266000000

USD

CY2020

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

637000000

USD

CY2020

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

637000000

USD

CY2020

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

599000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

325000000

USD

CY2018

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

515000000

USD

CY2020

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

38000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

175000000

USD

CY2018

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

415000000

USD

CY2020

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

637000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

500000000

USD

CY2018

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

930000000

USD

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

84457000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

78195000000

USD

CY2018

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

68651000000

USD

CY2020

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3588000000

USD

CY2019

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3591000000

USD

CY2018

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3244000000

USD

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2018

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

71895000000

USD

CY2020Q4

us-gaap

Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net

ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet

239548000000

USD

CY2020Q4

us-gaap

Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net

ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet

228459000000

USD

CY2020Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

11089000000

USD

CY2020Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

46000000

USD

CY2020Q4

us-gaap

Shortduration Insurance Contracts Liability For Unpaid Claims And Claim Adjustment Expense Other Reconciling Item

ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem

224000000

USD

CY2020Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

11359000000

USD

CY2020Q4

us-gaap

Long Term Debt

LongTermDebt

20035000000

USD

CY2019Q4

us-gaap

Long Term Debt

LongTermDebt

19385000000

USD

CY2020Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

700000000

USD

CY2019Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1598000000

USD

CY2020Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

19335000000

USD

CY2019Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17787000000

USD

CY2020Q4

us-gaap

Debt Instrument Face Amount

DebtInstrumentFaceAmount

159000000

USD

CY2020Q4

us-gaap

Debt Instrument Unamortized Discount

DebtInstrumentUnamortizedDiscount

49000000

USD

CY2020Q4

us-gaap

Convertible Debt Noncurrent

ConvertibleDebtNoncurrent

108000000

USD

CY2020Q4

us-gaap

Debt Instrument Convertible Carrying Amount Of The Equity Component

DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent

58000000

USD

CY2020

us-gaap

Debt Instrument Convertible Conversion Ratio1

DebtInstrumentConvertibleConversionRatio1

14.0808

CY2020Q4

us-gaap

Debt Instrument Convertible Conversion Price1

DebtInstrumentConvertibleConversionPrice1

71.0187

CY2020

us-gaap

Interest Paid

InterestPaid

794000000

USD

CY2019

us-gaap

Interest Paid

InterestPaid

755000000

USD

CY2018

us-gaap

Interest Paid

InterestPaid

728000000

USD

CY2020Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

950000000

USD

CY2020Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

1597000000

USD

CY2020Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

1027000000

USD

CY2020Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Four

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

1643000000

USD

CY2020Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

1253000000

USD

CY2020Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal After Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

13565000000

USD

CY2020Q4

antm

Gross Premium Tax Rate

GrossPremiumTaxRate

0.0235

CY2020Q4

antm

Merger Agreement Termination Fee

MergerAgreementTerminationFee

1850000000

USD

CY2020

us-gaap

Long Term Purchase Commitment Amount

LongTermPurchaseCommitmentAmount

1426000000

USD

CY2020

us-gaap

Share Based Compensation

ShareBasedCompensation

283000000

USD

CY2019

us-gaap

Share Based Compensation

ShareBasedCompensation

294000000

USD

CY2018

us-gaap

Share Based Compensation

ShareBasedCompensation

226000000

USD

CY2020

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

74000000

USD

CY2019

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

78000000

USD

CY2018

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

61000000

USD

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

190.28

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3100000

shares

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

1000000.0

shares

CY2020

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

271.61

CY2020

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

900000

shares

CY2020

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

136.89

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

273.91

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3100000

shares

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

230.00

CY2020

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y9M

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

280000000

USD

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

1600000

shares

CY2020Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-06-25

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

185.08

CY2020

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P5Y4M13D

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

217000000

USD

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1400000

shares

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

242.54

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

1300000

shares

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

272.37

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

1300000

shares

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

196.25

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

100000

shares

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

272.50

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1300000

shares

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

272.51

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0130

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0269

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0290

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2600

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2500

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.3000

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0140

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0100

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0130

CY2020

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y3M18D

CY2019

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

CY2018

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P3Y8M12D

CY2020Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

240000000

USD

CY2020Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-04-28

CY2020Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

68.66

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

55.48

CY2020Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-06-10

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

54.05

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

272.37

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

305.88

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

233.73

CY2020Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-01-28

CY2020Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-03-16

CY2020Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-03-27

CY2020Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

242000000

USD

CY2020Q3

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-07-28

CY2020Q3

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-09-10

CY2020Q3

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-09-25

CY2020Q3

us-gaap

Payments Of Dividends

PaymentsOfDividends

238000000

USD

CY2020Q4

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-10-27

CY2020Q4

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-12-07

CY2020Q4

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-12-22

CY2020Q4

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q4

us-gaap

Payments Of Dividends

PaymentsOfDividends

234000000

USD

CY2019Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-01-29

CY2019Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-03-18

CY2019Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-03-29

CY2019Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

206000000

USD

CY2019Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-04-23

CY2019Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-06-10

CY2019Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-06-25

CY2019Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

206000000

USD

CY2019Q3

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-07-23

CY2019Q3

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-09-10

CY2019Q3

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-09-25

CY2019Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q3

us-gaap

Payments Of Dividends

PaymentsOfDividends

204000000

USD

CY2019Q4

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-10-22

CY2019Q4

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-12-05

CY2019Q4

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-12-20

CY2019Q4

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q4

us-gaap

Payments Of Dividends

PaymentsOfDividends

202000000

USD

CY2020Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

1251000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

676000000

USD

CY2020

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

9400000

shares

CY2019

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

6300000

shares

CY2020

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

286.35

CY2019

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

268.65

CY2020

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

2700000000

USD

CY2019

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1701000000

USD

CY2020Q4

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

1092000000

USD

CY2019Q4

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

3792000000

USD

CY2020Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

1316000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

720000000

USD

CY2020Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

65000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

44000000

USD

CY2020Q4

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-302000000

USD

CY2019Q4

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-155000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

949000000

USD

CY2020Q4

antm

Non Credit Componentof Impairmentson Investments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

NonCreditComponentofImpairmentsonInvestmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

1000000

USD

CY2019Q4

antm

Non Credit Componentof Impairmentson Investments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

NonCreditComponentofImpairmentsonInvestmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

1000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

521000000

USD

CY2020Q4

antm

Accumulatedothercomprehensiveincomelossnoncreditcomponentofimpairmentsoninvestments

3000000

USD

CY2019Q4

antm

Accumulatedothercomprehensiveincomelossnoncreditcomponentofimpairmentsoninvestments

3000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities

2000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities

2000000

USD

CY2020

antm

Aoci Cash Flow Hedge Unrealized Gain Loss Before Tax

AOCICashFlowHedgeUnrealizedGainLossBeforeTax

-316000000

USD

CY2019

antm

Aoci Cash Flow Hedge Unrealized Gain Loss Before Tax

AOCICashFlowHedgeUnrealizedGainLossBeforeTax

-331000000

USD

CY2020Q4

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

66000000

USD

CY2019Q4

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

69000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-250000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-262000000

USD

CY2020Q4

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-749000000

USD

CY2019Q4

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-734000000

USD

CY2020Q4

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

0

USD

CY2019Q4

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

547000000

USD

CY2020Q4

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-3000000

USD

CY2019Q4

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

1000000

USD

CY2019Q4

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-25000000

USD

CY2020Q4

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-190000000

USD

CY2019Q4

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-188000000

USD

CY2020Q4

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

559000000

USD

CY2020Q4

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

12000000

USD

CY2019Q4

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

19000000

USD

CY2020Q4

antm

Deferred Tax Liability Postretirement Benefits

DeferredTaxLiabilityPostretirementBenefits

-2000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

2000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

-7000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

4000000

USD

CY2020Q4

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

6000000

USD

CY2019Q4

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-3000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Unrealized Currency Transaction Gains

DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains

1000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

1000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

5000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

150000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-296000000

USD

CY2020

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

478000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

695000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

-465000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

50000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

15000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

-47000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

428000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

680000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-418000000

USD

CY2020

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

0

USD

CY2019

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

0

USD

CY2018

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-2000000

USD

CY2020

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

12000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

-16000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

37000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

1000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-26000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

90000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

7000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

CY2018

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-1000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

446000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

690000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-474000000

USD

CY2020

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

100832000000

USD

CY2020

us-gaap

Direct Premiums Written

DirectPremiumsWritten

102479000000

USD

CY2019

us-gaap

Direct Premiums Written

DirectPremiumsWritten

91579000000

USD

CY2019

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

91131000000

USD

CY2018

us-gaap

Direct Premiums Written

DirectPremiumsWritten

83652000000

USD

CY2018

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

84030000000

USD

CY2020

us-gaap

Assumed Premiums Written

AssumedPremiumsWritten

3326000000

USD

CY2020

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

3356000000

USD

CY2019

us-gaap

Assumed Premiums Written

AssumedPremiumsWritten

3196000000

USD

CY2019

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

3087000000

USD

CY2018

us-gaap

Assumed Premiums Written

AssumedPremiumsWritten

1447000000

USD

CY2018

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

1442000000

USD

CY2020

us-gaap

Ceded Premiums Written

CededPremiumsWritten

79000000

USD

CY2019

us-gaap

Ceded Premiums Written

CededPremiumsWritten

45000000

USD

CY2019

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

45000000

USD

CY2018

us-gaap

Ceded Premiums Written

CededPremiumsWritten

51000000

USD

CY2018

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

51000000

USD

CY2020

us-gaap

Premiums Written Net

PremiumsWrittenNet

105726000000

USD

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

USD

CY2019

us-gaap

Premiums Written Net

PremiumsWrittenNet

94730000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2018

us-gaap

Premiums Written Net

PremiumsWrittenNet

85048000000

USD

CY2018

us-gaap

Premiums Earned Net

PremiumsEarnedNet

85421000000

USD

CY2020

antm

Percentage Of Amount Assumed To Net Premiums Written

PercentageOfAmountAssumedToNetPremiumsWritten

0.031

CY2020

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.032

CY2019

antm

Percentage Of Amount Assumed To Net Premiums Written

PercentageOfAmountAssumedToNetPremiumsWritten

0.034

CY2019

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.033

CY2018

antm

Percentage Of Amount Assumed To Net Premiums Written

PercentageOfAmountAssumedToNetPremiumsWritten

0.017

CY2018

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.017

CY2020

us-gaap

Premiums Written Net

PremiumsWrittenNet

105726000000

USD

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

USD

CY2019

us-gaap

Premiums Written Net

PremiumsWrittenNet

94730000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2018

us-gaap

Premiums Written Net

PremiumsWrittenNet

85048000000

USD

CY2018

us-gaap

Premiums Earned Net

PremiumsEarnedNet

85421000000

USD

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

85168000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

79110000000

USD

CY2018

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

70789000000

USD

CY2020

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

2967000000

USD

CY2020Q4

antm

Assumed Premiums Receivable

AssumedPremiumsReceivable

347000000

USD

CY2019Q4

antm

Assumed Premiums Receivable

AssumedPremiumsReceivable

324000000

USD

CY2020Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0321

CY2019Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0409

CY2019

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

2733000000

USD

CY2018

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

1179000000

USD

CY2020

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

90000000

USD

CY2019

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

57000000

USD

CY2018

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

73000000

USD

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2018

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

71895000000

USD

CY2020Q4

us-gaap

Assumed Liability For Unpaid Claims And Claims Adjustment Expense

AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

490000000

USD

CY2019Q4

us-gaap

Assumed Liability For Unpaid Claims And Claims Adjustment Expense

AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

471000000

USD

CY2020

antm

Assumed Unearned Income

AssumedUnearnedIncome

85000000

USD

CY2019

antm

Assumed Unearned Income

AssumedUnearnedIncome

114000000

USD

CY2020Q4

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

12000000

USD

CY2019Q4

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

11000000

USD

CY2020

us-gaap

Operating Lease Cost

OperatingLeaseCost

438000000

USD

CY2019

us-gaap

Operating Lease Cost

OperatingLeaseCost

198000000

USD

CY2020

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

50000000

USD

CY2019

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

46000000

USD

CY2020

us-gaap

Sublease Income

SubleaseIncome

9000000

USD

CY2019

us-gaap

Sublease Income

SubleaseIncome

16000000

USD

CY2020

us-gaap

Lease Cost

LeaseCost

479000000

USD

CY2019

us-gaap

Lease Cost

LeaseCost

228000000

USD

CY2018

us-gaap

Lease Cost

LeaseCost

207000000

USD

CY2020

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

258000000

USD

CY2020

us-gaap

Operating Lease Payments

OperatingLeasePayments

207000000

USD

CY2019

us-gaap

Operating Lease Payments

OperatingLeasePayments

176000000

USD

CY2020

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

384000000

USD

CY2019

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

112000000

USD

CY2020Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2019Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P6Y

CY2020Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

180000000

USD

CY2020Q4

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

197000000

USD

CY2020Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

156000000

USD

CY2020Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

125000000

USD

CY2020Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

88000000

USD

CY2020Q4

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

236000000

USD

CY2020Q4

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

982000000

USD

CY2020Q4

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

25000000

USD

CY2020Q4

us-gaap

Operating Lease Liability

OperatingLeaseLiability

957000000

USD

CY2020Q4

us-gaap

Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1

LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1

P12Y

CY2020

us-gaap

Lessee Operating Lease Lease Not Yet Commenced Description

LesseeOperatingLeaseLeaseNotYetCommencedDescription

are expected to commence on various dates during 2021 when the construction is complete and we take possession of the buildings.

CY2020Q4

antm

Lessee Operating Lease Lease Not Yet Commenced Expense

LesseeOperatingLeaseLeaseNotYetCommencedExpense

139000000

USD

CY2020

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

250800000

shares

CY2019

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

255500000

shares

CY2018

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

258100000

shares

CY2020

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

3500000

shares

CY2019

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

4800000

shares

CY2018

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

6100000

shares

CY2020

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

254300000

shares

CY2019

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

260300000

shares

CY2018

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

264200000

shares

CY2020

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

1200000

shares

CY2019

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

600000

shares

CY2018

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

300000

shares

CY2018Q2

us-gaap

Stock Issued During Period Shares New Issues

StockIssuedDuringPeriodSharesNewIssues

6000000.0

shares

CY2020

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

300000

shares

CY2019

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

200000

shares

CY2018

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

300000

shares

CY2020

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

4

segment

CY2020

us-gaap

Concentration Risk Percentage1

ConcentrationRiskPercentage1

0.203

CY2019

us-gaap

Concentration Risk Percentage1

ConcentrationRiskPercentage1

0.207

CY2018

us-gaap

Concentration Risk Percentage1

ConcentrationRiskPercentage1

0.198

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

USD

CY2020

us-gaap

Operating Income Loss

OperatingIncomeLoss

6360000000

USD

CY2020

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

638000000

USD

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2019

us-gaap

Operating Income Loss

OperatingIncomeLoss

5999000000

USD

CY2019

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

675000000

USD

CY2018

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

91341000000

USD

CY2018

us-gaap

Operating Income Loss

OperatingIncomeLoss

5426000000

USD

CY2018

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

652000000

USD

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

USD

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2018

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

91341000000

USD

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

USD

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2018

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

91341000000

USD

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2018

us-gaap

Net Investment Income

NetInvestmentIncome

970000000

USD

CY2020

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

182000000

USD

CY2019

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

67000000

USD

CY2018

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

-206000000

USD

CY2020

us-gaap

Revenues

121867000000

USD

CY2019

us-gaap

Revenues

104213000000

USD

CY2018

us-gaap

Revenues

92105000000

USD

CY2020

us-gaap

Operating Income Loss

OperatingIncomeLoss

6360000000

USD

CY2019

us-gaap

Operating Income Loss

OperatingIncomeLoss

5999000000

USD

CY2018

us-gaap

Operating Income Loss

OperatingIncomeLoss

5426000000

USD

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2018

us-gaap

Net Investment Income

NetInvestmentIncome

970000000

USD

CY2020

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

182000000

USD

CY2019

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

67000000

USD

CY2018

antm

Net Realized Gains Losses On Financial Instruments

NetRealizedGainsLossesOnFinancialInstruments

-206000000

USD

CY2020

us-gaap

Interest Expense

InterestExpense

784000000

USD

CY2019

us-gaap

Interest Expense

InterestExpense

746000000

USD

CY2018

us-gaap

Interest Expense

InterestExpense

753000000

USD

CY2020

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

361000000

USD

CY2019

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

338000000

USD

CY2018

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

358000000

USD

CY2020

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-36000000

USD

CY2019

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-2000000

USD

CY2018

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-11000000

USD

CY2020

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

6238000000

USD

CY2019

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

5985000000

USD

CY2018

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

5068000000

USD

CY2020Q4

us-gaap

Statutory Accounting Practices Statutory Capital And Surplus Required

StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired

5800000000

USD

CY2019Q4

us-gaap

Statutory Accounting Practices Statutory Capital And Surplus Required

StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired

5500000000

USD

CY2020Q1

us-gaap

Revenues

29621000000

USD

CY2020Q2

us-gaap

Revenues

29264000000

USD

CY2020Q3

us-gaap

Revenues

31158000000

USD

CY2020Q4

us-gaap

Revenues

31824000000

USD

CY2020Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2089000000

USD

CY2020Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

3149000000

USD

CY2020Q3

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

389000000

USD

CY2020Q4

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

611000000

USD

CY2020Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

6.03

CY2020Q1

us-gaap

Net Income Loss

NetIncomeLoss

1523000000

USD

CY2020Q2

us-gaap

Net Income Loss

NetIncomeLoss

2276000000

USD

CY2020Q3

us-gaap

Net Income Loss

NetIncomeLoss

222000000

USD

CY2020Q4

us-gaap

Net Income Loss

NetIncomeLoss

551000000

USD

CY2020Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

9.02

CY2020Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.88

CY2020Q4

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

2.23

CY2020Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

5.94

CY2020Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

8.91

CY2020Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.87

CY2020Q4

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

2.19

CY2019Q1

us-gaap

Revenues

24666000000

USD

CY2019Q2

us-gaap

Revenues

25466000000

USD

CY2019Q3

us-gaap

Revenues

26674000000

USD

CY2019Q4

us-gaap

Revenues

27407000000

USD

CY2019Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1945000000

USD

CY2019Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1453000000

USD

CY2019Q3

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1489000000

USD

CY2019Q4

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1098000000

USD

CY2019Q1

us-gaap

Net Income Loss

NetIncomeLoss

1551000000

USD

CY2019Q2

us-gaap

Net Income Loss

NetIncomeLoss

1139000000

USD

CY2019Q3

us-gaap

Net Income Loss

NetIncomeLoss

1183000000

USD

CY2019Q4

us-gaap

Net Income Loss

NetIncomeLoss

934000000

USD

CY2019Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

6.03

CY2019Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

4.44

CY2019Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

4.64

CY2019Q4

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

3.69

CY2019Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

5.91

CY2019Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.36

CY2019Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.55

CY2019Q4

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

3.62

Name	View Source	Status
0001156039-21-000012-index-headers.html	Edgar Link	pending
0001156039-21-000012-index.html	Edgar Link	pending
0001156039-21-000012.txt	Edgar Link	pending
0001156039-21-000012-xbrl.zip	Edgar Link	pending
antm-20201231.htm	Edgar Link	pending
antm-20201231.xsd	Edgar Link	pending
antm-20201231_cal.xml	Edgar Link	unprocessable
antm-20201231_def.xml	Edgar Link	unprocessable
antm-20201231_g1.jpg	Edgar Link	pending
antm-20201231_htm.xml	Edgar Link	completed
antm-20201231_lab.xml	Edgar Link	unprocessable
antm-20201231_pre.xml	Edgar Link	unprocessable
exhibit-1011bluecrosslicen.htm	Edgar Link	pending
exhibit1012-blueshieldlice.htm	Edgar Link	pending
exhibit1062020anthemdirect.htm	Edgar Link	pending
exhibit21-20201231for10xk.htm	Edgar Link	pending
exhibit23-20201231for10xk.htm	Edgar Link	pending
exhibit311-20201231for10xk.htm	Edgar Link	pending
exhibit312-20201231for10xk.htm	Edgar Link	pending
exhibit321-20201231for10xk.htm	Edgar Link	pending
exhibit322-20201231for10xk.htm	Edgar Link	pending
exhibit48-2020securitiesex.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R139.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2020 Q4 Form 10-K Financial Statement

#000115603921000012 Filed on February 18, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2020 Q4 Form 10-K Financial Statement

#000115603921000012 Filed on February 18, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv